Patents Examined by Gerald G Leffers, Jr.
-
Patent number: 6284484Abstract: The present invention provides a process for the expression in appropriate host cells of recombinant DNA which is under the control of an inducible promotor. In order to obtain the soluble form of recombinant protein, which would usually be obtained in insoluble form, the induction of the promotor is limited to less than 10% of the maximum induction in comparison with a standard system and the transcription rate of the DNA coding for the protein is correspondingly limited.Type: GrantFiled: June 27, 1991Date of Patent: September 4, 2001Assignee: Roche Diagnostics GmbHInventors: Erhard Kopetzki, Günther Schumacher
-
Patent number: 6277633Abstract: A recombinant lentiviral vector expression system comprises a first vector that comprises a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome. The vector contains at least one defect in at least one gene encoding an EIAV structural protein, but is preferably a gaglpol expression vector. The expression system further comprises a second vector, also comprising a nucleic acid sequence of at least part of the Equine Infectious Anemia Virus (EIAV) genome, and additionally containing a multiple cloning site wherein a heterologous gene may be inserted. The expression system also comprises a third vector which expresses a viral envelope protein. The first and third vectors are packaging signal-defective. When the expression system is transfected into a lentivirus-permissive cell, replication-defective EIAV particles may be produced, which particles are useful in delivering heterologous genes to a broad range of both dividing and non-dividing cells.Type: GrantFiled: May 12, 1998Date of Patent: August 21, 2001Assignee: The University of North Carolina at Chapel HillInventor: John C. Olsen
-
Patent number: 6277608Abstract: Recombinational cloning is provided by the use of nucleic acids, vectors and methods, in vitro and in vivo, for moving or exchanging segments of DNA molecules using engineered recombination sites and recombination proteins to provide chimeric DNA molecules that have the desired characteristic(s) and/or DNA segment(s).Type: GrantFiled: April 22, 1999Date of Patent: August 21, 2001Assignee: Invitrogen CorporationInventors: James L. Hartley, Michael A. Brasch, Gary F. Temple, Donna K. Fox
-
Patent number: 6274345Abstract: The present invention relates to expression vectors containing a gene encoding outer membrane protein C(OmpC) from Escherichia coli as a cell surface anchoring motif, more specifically, to expression vectors comprising a gene encoding OmpC which is designed to express a gene of foreign protein in fused form with OmpC on the cell surface of Escherichia coli, and a method for displaying the desired protein on the surface of the bacteria employing the OmpC as a cell surface anchoring motif. In accordance with the present invention, the desired protein can be expressed efficiently on the cell surface of bacteria so that the expressed protein can be applied to a variety of applications such as live vaccine development, peptide libraries screening, antibody production, environmental bioadsorbent, whole cell catalysis, and biosensor development.Type: GrantFiled: February 18, 2000Date of Patent: August 14, 2001Assignee: Korea Advanced Institute of Science and TechnologyInventors: Sang Yup Lee, Zhaohui Xu, Jong Hyun Choi
-
Patent number: 6271034Abstract: The present invention provides a method for high frequency of allelic exchange in the slow-growing mycobacteria using in vitro generated specialized transducing mycobacteriophages, as well as the recombinant slow-growing mycobacteria generated using the disclosed method. A transducing mycobacteriophage of the present invention comprises a conditional mycobacteriophage containing an E. coli bacteriophage lambda cosmid inserted into a non-essential region of the mycobacteriophage, said cosmid containing a mutated DNA substrate which is homologous to a wildtype nucleic acid sequence of a slow-growing mycobacterium. When slow-growing mycobacteria infected with the conditional transducing phage are cultured under conditions wherein the conditional transducing phage does not replicate, the mutated DNA substrate is incorporated into the chromosomal DNA of the slow-growing mycobacteria by homologous recombination, thereby generating the recombinant slow-growing mycobacteria of the present invention.Type: GrantFiled: July 8, 1999Date of Patent: August 7, 2001Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Stoyan S. Bardarov, William R. Jacobs, Jr.
-
Patent number: 6271360Abstract: The invention concerns the introduction of predetermined genetic changes in target genes of a living cell by introducing an oligodeoxynucleotide encoding the predetermined change. The oligodeoxynucleotides are effective in mammalian, avian, plant and bacterial cells. Specific end modifications that greatly increase the effectiveness of the oligodeoxynucleotides in bacteria are described. Surprisingly, unmodified oligodeoxynucleotides can be as effective in mammaliancells, including in vivo hepatocytes, as the modified nucleotides and can be as effective or more effective than chimeric oligonucleotides that consist of a mixture of deoxynucleotides and 2′-O-methyl ribonucleotides.Type: GrantFiled: August 27, 1999Date of Patent: August 7, 2001Assignee: ValiGen (US), Inc.Inventors: Richard A. Metz, Bruce L. Frank, Debra M. Walther
-
Patent number: 6268178Abstract: This invention relates to a method for enhancing the production of biologically active proteins and peptides in bacterial cells by infecting bacterial cells of the producer strain, which contain a plasmid with one or more targeted genes, with bacteriophage &lgr; with or without the targeted gene(s). The phage increases synthesis of the targeted protein and induces lysis of the producer strain cells. Super-production is achieved by cultivating the producer strain cells under culture conditions that delay lytic development of the phage. The biologically active proteins and peptides subsequently accumulate in a soluble form in the culture medium as the cells of the producer strain are lysed by the phage.Type: GrantFiled: May 25, 1999Date of Patent: July 31, 2001Assignee: Phage Biotechnology Corp.Inventors: Vitaliy A. Kordyum, Svetlana I. Chernykh, Irina Y. Slavchenko, Oleksandr F. Vozianov
-
Patent number: 6258595Abstract: A method for producing recombinant adeno-associated virus in the absence of contaminating helper virus or wild-type virus involves culturing a mammalian host cell containing an rAd/AAV hybrid virus, an AAV rep sequence and an AAV cap sequence under the control of regulatory sequences directing expression thereof. The rAd/AAV hybrid virus contains a rAAV construct to be packaged into an AAV virion in a backbone containing the adenoviral sequences necessary to express E1a and E1b gene products and to permit replication of the hybrid virus. The method of the invention permits replication of the hybrid virus and production of rAAV virion in this host cell in the absence of a helper virus and obviates a subsequent purification step to purify rAAV from contaminating virus.Type: GrantFiled: September 23, 1999Date of Patent: July 10, 2001Assignee: The Trustees of the University of PennsylvaniaInventors: Guang-Ping Gao, James M. Wilson
-
Patent number: 6258560Abstract: Processes are described for recovering heterologous polypeptide from bacterial cells, including the periplasm and cytoplasm. One process involves culturing the bacterial cells, which cells comprise nucleic acid encoding phage lysozyme and nucleic acid encoding a protein that displays DNA-digesting activity, wherein these nucleic acids are linked to a first promoter, and nucleic acid encoding the heterologous polypeptide, which nucleic acid is linked to a second promoter, under certain conditions to produce a broth lysate; and recovering accumulated heterologous polypeptide from the broth lysate.Type: GrantFiled: June 29, 2000Date of Patent: July 10, 2001Assignee: Genentech, Inc.Inventors: Woon-Lam Susan Leung, James R. Swartz
-
Patent number: 6248559Abstract: A preventive or therapeutic agent for Alzheimer's disease which comprises a substance exhibiting an inhibitory action to tau-protein kinase I as an effective component is provided. A pharmaceutical composition comprising said agent and a method of inhibiting neuronal cell death in the brain are also provided.Type: GrantFiled: December 21, 1998Date of Patent: June 19, 2001Assignee: Mitsubishi Chemical CorporationInventors: Akihiko Takashima, Toshimitsu Hoshino, Kazutomo Imahori, Ken-ichi Saito, Akiko Shiratsuchi, Showbu Sato
-
Patent number: 6248525Abstract: Two methodologies are provided: the first provides a means for rapidly and efficiently identifying essential and functional genes; and the second provides a means for obtaining biologically active nucleic molecules (ribozymes, EGSs, and antisense,) which can be used to inactivate functional genes. In the first method, a library of EGSs is prepared based on all possible known compositions. In a preferred embodiment, the EGSs are twelve or thirteen-mers for targeting bacterial RNAse to cleave a substrate. This library is added to the cells containing the genes to be screened, for example, E. coli. Those cells in which the EGS causes a loss of viability, or other phenotype, are identified. The EGS(s) responsible for the loss of viability are analyzed, and the resulting sequence information used to identify the gene within the known genomic sequences.Type: GrantFiled: November 20, 1998Date of Patent: June 19, 2001Assignee: Yale UniversityInventor: Timothy W. Nilsen
-
Patent number: 6245504Abstract: The present invention is directed to isolated transducing phages, methods of isolating transducing phages, and methods of using transducing phages including, for instance, transferring at least one nucleic acid fragment from a donor microbe to a recipient microbe, and producing a secondary metabolite from a microbe. The transducing phages typically have a broad host range, and transduce microbes in the Order Actinomycetales, in particular in the Family Streptomycetaceae, including Streptomyces coelicolor, Streptomyces lividans, Streptomyces venezuelae, Streptomyces avermitilis, and Saccharopolyspora erythraea. The transducing phages can be specialized transducing phages or generalized transducing phages.Type: GrantFiled: May 25, 1999Date of Patent: June 12, 2001Assignee: The University of Georgia Research Foundation, Inc.Inventors: Janet Westpheling, Julie A. Burke
-
Patent number: 6239261Abstract: A process for the preparation of a concentrate of von Willebrand factor is described, entailing a solution of a complex of this factor with factor VIII:C being optionally pasteurized and treated with an anion exchanger, there being no binding of the von Willebrand factor.Type: GrantFiled: June 2, 1994Date of Patent: May 29, 2001Assignee: Aventis Behring GmbHInventors: Norbert Heimburger, Gerhard Kumpe, Klaus Wellner
-
Patent number: 6235521Abstract: A &lgr; phage with a nuclear localization signal has been obtained by constructing a vector capable of expressing a fused protein between a gpD protein constituting the head of a &lgr; phage and a nuclear localization signal sequence, transforming Escherichia coli with this vector, and propagating a mutant &lgr; phage which cannot express the gpD protein in E. coli in this transformant. It has been confirmed that the resulting &lgr; phage is capable of packaging &lgr; phage DNAs of 80% and 100% genome sizes. After further confirming that the nuclear localization signal exposed on the outside of the head of this phage, this phage has been microinjected into cells to analyze its nuclear localization activity. Thus, it has been clarified that this phage has a nuclear localization activity.Type: GrantFiled: September 10, 1999Date of Patent: May 22, 2001Assignee: Dnavec ResearchInventors: Mahito Nakanishi, Emi Nagoshi, Teruo Akuta, Katsuo Takeda, Mamoru Hasegawa
-
Patent number: 6207384Abstract: The invention features a general system for the identification of essential genes in organisms. This system is applicable to the discovery of novel target genes for antimicrobial compounds, as well as to the discovery of genes that enhance cell growth or viability.Type: GrantFiled: March 26, 1999Date of Patent: March 27, 2001Assignees: The General Hospital Corporation, Trustees of Tufts College, President and Fellows of Harvard CollegeInventors: John J. Mekalanos, Brian J. Akerley, Eric J. Rubin, Andrew Camilli
-
Patent number: 6207803Abstract: Human REQUIEM polypeptides and DNA (RNA) encoding such REQUIEM and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such REQUIEM for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control of embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility.Type: GrantFiled: January 19, 1999Date of Patent: March 27, 2001Assignee: SmithKline Beecham CorporationInventors: Mitchell S Gross, Mark Robert Hurle, Kristine Kay Kikly
-
Patent number: 6204062Abstract: The invention provides in one embodiment a composition which is a linear DNA molecule having a desired replacement sequence, and second and third sequences substantially homologous to non-identical portions of the gene and having proximal and distal ends, the proximal ends flanking the desired replacement sequence and the distal ends having a terminating nucleotide analog at each end of the molecule. Another embodiment of the invention provides methods, by blocking the 3′ ends of transforming DNA with 2′3′ dideoxynucleotides, to reduce the frequency of end-mediated DNA insertion. These methods introduce only one copy of the selectable gene at the target locus to achieve a precise gene disruption, reducing or eliminating undesirable and multiple insertions that occur both non-homologously and at the targeted locus.Type: GrantFiled: August 10, 1999Date of Patent: March 20, 2001Assignee: Trustees of Amherst CollegeInventor: David I. Ratner
-
Patent number: 6194205Abstract: T cells having a desired antigen specificity are stimulated by (a) introducing immortalizing genes into antigen-presenting cells in a manner permitting regulation of the expression and/or function of at least one of these genes to achieve conditionally immortalized antigen-presenting cells; (b) introducing a gene encoding the desired antigen into the immortalized cells in a manner permitting the antigen to be expressed after the expression and/or abolishment of the function of at least one of the immortalizing genes stops; (c) expanding the immortalized antigen-presenting cells by expression and/or functional activation of the immortalizing genes; (d) completing the proliferation of the immortalized antigen-presenting cells by stopping the expression and/or abolishing the function of at least one of the controllable immortalizing genes; (e) continuing the expression of the antigen; (f) adding leucocytic cells including T cells and cultivating the cell mixture to stimulate the T cells directed against the desiType: GrantFiled: September 14, 1998Date of Patent: February 27, 2001Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Martin Staege, Bettina Kempkes, Georg W. Bornkamm, Wolfgang Hammerschmidt, Ursula Zimber-Strobl, Axel Polack
-
Patent number: 6171845Abstract: The invention relates to a process for the preparation and improvement of D-pantothenic acid-producing microorganisms by amplification of nucleotide sequences which code for ketopantoate reductase, in particular the panE gene, individually or in combination with one another, and optionally additionally of the ilvC gene, the microorganisms containing these nucleotide sequences, and a process for the preparation of D-pantothenic acid comprising fermentation of these microorganisms, concentration of pantothenic acid in the medium or in the cells of the microorganisms, and isolation of the D-pantothenic acid.Type: GrantFiled: October 12, 1999Date of Patent: January 9, 2001Assignee: Degussa-Huls AGInventors: Frank Elischweski, Jorn Kalinowski, Alfred Puhler, Nicole Dusch, Jurgen Dohmen, Mike Farwick, Georg Thierbach
-
Patent number: 6168942Abstract: The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the Npro protease gene. The invention includes the attenuated viruses made by this method, antibodies generated using these viruses, and vaccines that can be used for immunizing cattle.Type: GrantFiled: November 4, 1999Date of Patent: January 2, 2001Assignee: Pfizer Inc.Inventors: Xuemei Cao, Michael G. Sheppard